<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02140060</url>
  </required_header>
  <id_info>
    <org_study_id>C-14-003</org_study_id>
    <nct_id>NCT02140060</nct_id>
  </id_info>
  <brief_title>6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension</brief_title>
  <official_title>A 6-Week Proof-of-Concept Study Evaluating the Safety and IOP-Lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate Travoprost/Brinzolamide fixed combination
      (Trav/Brinz) administered twice daily as compared to each of its marketed components
      (TRAVATAN Z® solution and AZOPT® suspension) and to the unfixed combination of TRAVATAN Z®
      plus AZOPT® in lowering intraocular pressure (IOP).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was divided into two phases conducted in sequence. Phase I was the
      Screening/Eligibility Phase, which included a Screening Visit, followed by two Eligibility
      Visits. Phase II was the randomized, double-masked, 6-week Treatment Phase which included
      on-therapy visits at Week 2 and Week 6. Travoprost was administered in 1 of 3 concentration
      levels (A-C), where A=lowest and C=highest.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean IOP at Week 6</measure>
    <time_frame>Week 6, 8 AM, 10 AM, 12 PM, 4 PM, and 8 PM</time_frame>
    <description>IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in millimeters of mercury (mmHg). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). One eye (study eye) was used for the analysis.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">327</enrollment>
  <condition>Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>TravA/Brinz</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Level A / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TravB/Brinz</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Level B / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TravC/Brinz</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Level C / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZOPT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Brinzolamide 1% ophthalmic suspension, 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TRAV Z</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Brinzolamide suspension vehicle, 1 drop twice daily in the treated eye(s) morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TRAV Z + AZOPT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Brinzolamide 1% ophthalmic suspension, 1 drop twice daily in the treated eye(s) twice daily morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose Level A / Brinzolamide 1% ophthalmic suspension</intervention_name>
    <description>Fixed combination</description>
    <arm_group_label>TravA/Brinz</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose Level B / Brinzolamide 1% ophthalmic suspension</intervention_name>
    <description>Fixed combination</description>
    <arm_group_label>TravB/Brinz</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose Level C / Brinzolamide 1% ophthalmic suspension</intervention_name>
    <description>Fixed combination</description>
    <arm_group_label>TravC/Brinz</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brinzolamide 1% ophthalmic suspension AZOPT®</intervention_name>
    <arm_group_label>AZOPT</arm_group_label>
    <arm_group_label>TRAV Z + AZOPT</arm_group_label>
    <other_name>AZOPT®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost 0.004% ophthalmic solution TRAVATAN Z®</intervention_name>
    <arm_group_label>TRAV Z</arm_group_label>
    <arm_group_label>TRAV Z + AZOPT</arm_group_label>
    <other_name>TRAVATAN Z®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost solution vehicle</intervention_name>
    <description>Inactive ingredients used for masking purposes</description>
    <arm_group_label>TravA/Brinz</arm_group_label>
    <arm_group_label>TravB/Brinz</arm_group_label>
    <arm_group_label>TravC/Brinz</arm_group_label>
    <arm_group_label>AZOPT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brinzolamide suspension vehicle</intervention_name>
    <description>Inactive ingredients used for masking purposes</description>
    <arm_group_label>TRAV Z</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with open-angle glaucoma (including open-angle glaucoma with
             pseudoexfoliation or pigment dispersion) or ocular hypertension;

          -  IOP within the protocol-specified range at both the Eligibility 1 and 2 Visits. Mean
             IOP must not be &gt;36 mmHg at any time point;

          -  Able to understand and sign an informed consent form;

          -  Other protocol-specified inclusion criteria may apply.

        Exclusion Criteria:

          -  Woman of childbearing potential who is currently pregnant, intends to become pregnant
             during the study period, breastfeeding, or not using adequate birth control methods to
             prevent pregnancy throughout the study;

          -  Unable to discontinue all IOP-lowering ocular medication(s) per the appropriate
             washout schedule prior to the E1 Visit;

          -  Chronic, recurrent or severe inflammatory eye disease;

          -  Ocular trauma within the past 6 months prior to the Screening Visit;

          -  Ocular infection or ocular inflammation within the past 3 months prior to the
             Screening Visit;

          -  Clinically relevant or progressive retinal disease such as retinal degeneration,
             diabetic retinopathy, or retinal detachment;

          -  Best-corrected visual acuity (BCVA) score worse than 55 ETDRS letters (equivalent to
             approximately 0.60 logMAR, 20/80 Snellen, or 0.25 decimal);

          -  Other ocular pathology (including severe dry eye) that may, in the opinion of the
             Investigator, preclude the administration of a topical prostaglandin analogue or
             topical carbonic anhydrase inhibitor;

          -  Intraocular surgery within the past 6 months prior to the Screening Visit;

          -  Ocular laser surgery within the past 3 months prior to the Screening Visit;

          -  Any abnormality preventing reliable applanation tonometry;

          -  Any other conditions including severe illness which would make the subject, in the
             opinion of the Investigator, unsuitable for the study;

          -  History of hepatic or renal disease that would preclude the safe administration of a
             carbonic anhydrase inhibitor (CAI) in the opinion of the Investigator;

          -  Hypersensitivity to prostaglandin analogues, topical or oral CAIs, sulfonamide
             derivatives, or to any component of the study medications in the opinion of the
             Investigator;

          -  Recent (within 4 weeks of the Eligibility 1 Visit) use of high dose (&gt; 1 g daily)
             salicylate therapy;

          -  Use of any additional topical or systemic ocular hypotensive medication during the
             study;

          -  Concurrent use of glucocorticoids administered by any route;

          -  Less than 30 days stable dosing regimen before the Screening Visit of any medications
             (excluding the IOP-lowering treatments) or substances administered by any route and
             used on a chronic basis that may affect IOP (ie, β adrenergic blocking agents);

          -  Therapy with another investigational agent within 30 days prior to the Screening
             Visit;

          -  Other protocol-specified exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sr. Clinical Manager, GCRA, Pharma</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2014</study_first_submitted>
  <study_first_submitted_qc>May 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2014</study_first_posted>
  <results_first_submitted>November 24, 2015</results_first_submitted>
  <results_first_submitted_qc>November 24, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 29, 2015</results_first_posted>
  <last_update_submitted>November 24, 2015</last_update_submitted>
  <last_update_submitted_qc>November 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <keyword>Ocular</keyword>
  <keyword>Hypertension</keyword>
  <keyword>OAG</keyword>
  <keyword>POAG</keyword>
  <keyword>OHT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Travoprost</mesh_term>
    <mesh_term>Brinzolamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from 19 study centers located in the US.</recruitment_details>
      <pre_assignment_details>Of the 327 enrolled, 61 subjects were discontinued prior to randomization. This reporting group includes all randomized subjects (266).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TravA/Brinz</title>
          <description>Fixed combination, 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks</description>
        </group>
        <group group_id="P2">
          <title>TravB/Brinz</title>
          <description>Fixed combination, 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks</description>
        </group>
        <group group_id="P3">
          <title>TravC/Brinz</title>
          <description>Fixed combination, 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks</description>
        </group>
        <group group_id="P4">
          <title>TRAV Z</title>
          <description>Suspension vehicle, 1 drop twice daily in the treated eye(s) morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks</description>
        </group>
        <group group_id="P5">
          <title>AZOPT</title>
          <description>Ophthalmic suspension, 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night for 6 weeks</description>
        </group>
        <group group_id="P6">
          <title>TRAV Z + AZOPT</title>
          <description>Ophthalmic suspension, 1 drop twice daily in the treated eye(s) twice daily morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="44"/>
                <participants group_id="P4" count="45"/>
                <participants group_id="P5" count="45"/>
                <participants group_id="P6" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="44"/>
                <participants group_id="P4" count="43"/>
                <participants group_id="P5" count="44"/>
                <participants group_id="P6" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This analysis population includes all subjects who were randomized, received study medication, and completed at least 1 scheduled on-therapy study visit.</population>
      <group_list>
        <group group_id="B1">
          <title>TravA/Brinz</title>
          <description>Fixed combination, 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks</description>
        </group>
        <group group_id="B2">
          <title>TravB/Brinz</title>
          <description>Fixed combination, 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks</description>
        </group>
        <group group_id="B3">
          <title>TravC/Brinz</title>
          <description>Fixed combination, 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks</description>
        </group>
        <group group_id="B4">
          <title>TRAV Z</title>
          <description>Suspension vehicle, 1 drop twice daily in the treated eye(s) morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks</description>
        </group>
        <group group_id="B5">
          <title>AZOPT</title>
          <description>Ophthalmic suspension, 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night for 6 weeks</description>
        </group>
        <group group_id="B6">
          <title>TRAV Z + AZOPT</title>
          <description>Ophthalmic suspension, 1 drop twice daily in the treated eye(s) twice daily morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="44"/>
            <count group_id="B4" value="45"/>
            <count group_id="B5" value="45"/>
            <count group_id="B6" value="43"/>
            <count group_id="B7" value="265"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.4" spread="10.7"/>
                    <measurement group_id="B2" value="66.2" spread="10.4"/>
                    <measurement group_id="B3" value="64.4" spread="11.2"/>
                    <measurement group_id="B4" value="64.2" spread="10.4"/>
                    <measurement group_id="B5" value="63.1" spread="8.4"/>
                    <measurement group_id="B6" value="65.3" spread="10.6"/>
                    <measurement group_id="B7" value="64.8" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="24"/>
                    <measurement group_id="B7" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean IOP at Week 6</title>
        <description>IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in millimeters of mercury (mmHg). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). One eye (study eye) was used for the analysis.</description>
        <time_frame>Week 6, 8 AM, 10 AM, 12 PM, 4 PM, and 8 PM</time_frame>
        <population>This analysis population includes all subjects who were randomized, received study medication, and completed at least 1 scheduled on-therapy study visit, based upon a last on-therapy carried forward (LOCF) analysis. Here, &quot;n&quot; is the number of subjects with non-missing values at the specific time point for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>TravA/Brinz</title>
            <description>Fixed combination, 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>TravB/Brinz</title>
            <description>Fixed combination, 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>TravC/Brinz</title>
            <description>Fixed combination, 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks</description>
          </group>
          <group group_id="O4">
            <title>TRAV Z</title>
            <description>Suspension vehicle, 1 drop twice daily in the treated eye(s) morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks</description>
          </group>
          <group group_id="O5">
            <title>AZOPT</title>
            <description>Ophthalmic suspension, 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night for 6 weeks</description>
          </group>
          <group group_id="O6">
            <title>TRAV Z + AZOPT</title>
            <description>Ophthalmic suspension, 1 drop twice daily in the treated eye(s) twice daily morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean IOP at Week 6</title>
          <description>IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in millimeters of mercury (mmHg). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). One eye (study eye) was used for the analysis.</description>
          <population>This analysis population includes all subjects who were randomized, received study medication, and completed at least 1 scheduled on-therapy study visit, based upon a last on-therapy carried forward (LOCF) analysis. Here, &quot;n&quot; is the number of subjects with non-missing values at the specific time point for each arm, respectively.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="45"/>
                <count group_id="O6" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>8 AM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" spread="0.52"/>
                    <measurement group_id="O2" value="18.7" spread="0.48"/>
                    <measurement group_id="O3" value="19.9" spread="0.58"/>
                    <measurement group_id="O4" value="19.3" spread="0.48"/>
                    <measurement group_id="O5" value="22.0" spread="0.45"/>
                    <measurement group_id="O6" value="20.3" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 AM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9" spread="0.47"/>
                    <measurement group_id="O2" value="17.2" spread="0.35"/>
                    <measurement group_id="O3" value="18.2" spread="0.55"/>
                    <measurement group_id="O4" value="17.4" spread="0.47"/>
                    <measurement group_id="O5" value="19.7" spread="0.50"/>
                    <measurement group_id="O6" value="18.2" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 PM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9" spread="0.47"/>
                    <measurement group_id="O2" value="17.3" spread="0.50"/>
                    <measurement group_id="O3" value="17.7" spread="0.51"/>
                    <measurement group_id="O4" value="17.2" spread="0.50"/>
                    <measurement group_id="O5" value="19.5" spread="0.53"/>
                    <measurement group_id="O6" value="18.0" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4PM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" spread="0.46"/>
                    <measurement group_id="O2" value="17.5" spread="0.43"/>
                    <measurement group_id="O3" value="17.3" spread="0.46"/>
                    <measurement group_id="O4" value="17.6" spread="0.44"/>
                    <measurement group_id="O5" value="19.1" spread="0.50"/>
                    <measurement group_id="O6" value="18.0" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 PM, n=44, 44, 44, 43, 45, 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" spread="0.43"/>
                    <measurement group_id="O2" value="17.5" spread="0.39"/>
                    <measurement group_id="O3" value="17.2" spread="0.40"/>
                    <measurement group_id="O4" value="17.3" spread="0.43"/>
                    <measurement group_id="O5" value="19.3" spread="0.48"/>
                    <measurement group_id="O6" value="18.1" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were collected for the duration of a subject’s participation in the study (up to 11 weeks). AEs were reported as pre-treatment and treatment-emergent.</time_frame>
      <desc>An AE was defined as any untoward medical occurrence in a subject who was administered a study medication, regardless of whether or not the event had a causal relationship with the medication. AEs were obtained through solicited and spontaneous comments from study subjects, and through observations by the study Investigator.</desc>
      <group_list>
        <group group_id="E1">
          <title>TravA/Brinz</title>
          <description>Fixed combination, 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks</description>
        </group>
        <group group_id="E2">
          <title>TravB/Brinz</title>
          <description>Fixed combination, 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks</description>
        </group>
        <group group_id="E3">
          <title>TravC/Brinz</title>
          <description>Fixed combination, 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks</description>
        </group>
        <group group_id="E4">
          <title>TRAV Z</title>
          <description>Suspension vehicle, 1 drop twice daily in the treated eye(s) morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks</description>
        </group>
        <group group_id="E5">
          <title>AZOPT</title>
          <description>Ophthalmic suspension, 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night for 6 weeks</description>
        </group>
        <group group_id="E6">
          <title>TRAV Z + AZOPT</title>
          <description>Ophthalmic suspension, 1 drop twice daily in the treated eye(s) twice daily morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks</description>
        </group>
        <group group_id="E7">
          <title>Pre-treatment</title>
          <description>All subjects who signed an informed consent to participate in the study</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="327"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="327"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="327"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="327"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="327"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="327"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor reserves the right of prior review of any publication or presentation of information related to the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Project Lead, GCRA, Pharma</name_or_title>
      <organization>Alcon Research, Ltd.</organization>
      <phone>1-888-451-3937</phone>
      <email>alcon.medinfo@alcon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

